

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

October 28, 2024

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services  
25<sup>th</sup> Floor, P. J. Towers,  
Dalal Street, Mumbai-400001  
Script Id: 506365

Subject: Outcome of Board Meeting Held on Monday, October 28, 2024

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. October 28, 2024, approved the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2024, along with the Limited Review Report thereon.


We are enclosing herewith, a copy of the Un-Audited Financial Results for the quarter and half year ended September 30, 2024, along with the Limited Review Report thereon by auditor and cash flow statement and statement of assets and liabilities for the half year ended on 30th September 2024.

The Meeting commenced at 04.00 p.m. and concluded at 04.55 p.m.

Thanking You.

Yours Faithfully,

For CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI  
DIRECTOR  
(DIN -03063364)



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2024

(Rupees in Thousand)							
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30th Sept 2024	30th June 2024	30th Sept 2023	30th Sept 2024	30th Sept 2023	31st March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	-	-	-	-	-	-
II	Other Income	6,310	3,018	4,599	9,327	8,892	18,382
III	<b>Total Revenue (I + II)</b>	<b>6,310</b>	<b>3,018</b>	<b>4,599</b>	<b>9,327</b>	<b>8,892</b>	<b>18,382</b>
IV	<b>Expenses</b>						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	54	54	54	108	77	185
	(5) Depreciation and Amortisation Expenses	14	14	21	27	42	83
	(6) Administrative and Other Expenses	142	484	130	626	617	1,679
	(7) Finance Costs	-	-	-	-	-	-
	<b>Total Expenses</b>	<b>209</b>	<b>552</b>	<b>205</b>	<b>761</b>	<b>736</b>	<b>1,946</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>6,100</b>	<b>2,466</b>	<b>4,394</b>	<b>8,566</b>	<b>8,156</b>	<b>16,436</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>6,100</b>	<b>2,466</b>	<b>4,394</b>	<b>8,566</b>	<b>8,156</b>	<b>16,436</b>
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>6,100</b>	<b>2,466</b>	<b>4,394</b>	<b>8,566</b>	<b>8,156</b>	<b>16,436</b>
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	1,662
	(2) Tax Adjustment Previous Year	-	-	-	-	-	4
	(3) Deferred Tax	-	-	-	-	-	1,688
	(4) MAT Credit Entitlement	-	-	-	-	-	1,078
XI	<b>Profit/(Loss) for the period from continuing operations (IX - X)</b>	<b>6,100</b>	<b>2,466</b>	<b>4,394</b>	<b>8,566</b>	<b>8,156</b>	<b>12,004</b>
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	<b>Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>6,100</b>	<b>2,466</b>	<b>4,394</b>	<b>8,566</b>	<b>8,156</b>	<b>12,004</b>
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XVII	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>6,100</b>	<b>2,466</b>	<b>4,394</b>	<b>8,566</b>	<b>8,156</b>	<b>12,004</b>
XVIII	<b>Earnings per Share :</b>						
	(1) Basic	4.07	1.64	2.93	5.71	5.44	8.00
	(2) Diluted						

### Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2024 have been reviewed by the Audit Committee in their Meeting held on 28.10.2024 and approved by the Board of Directors of its Meeting held on 28.10.2024. The Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Date : 28/10/2024  
Place : Mumbai



For Chemo Pharma Laboratories Limited

*Ashok Somani*  
Ashok Somani

Director  
DIN : 03063364

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE STATEMENT OF ASSETS & LIABILITIES FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER, 2024

(Rupees in Thousand)

Sr. No.	PARTICULARS	As on Half Year 30.09.2024 Unaudited	As at 31.03.2024 Audited
1	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	(a) Property, Plant & Equipment	150	178
	(b) Financial Assets		
	(i) Investment	43,868	43,975
	(ii) Loans	23,495	23,495
	<b>Total Non-Current Assets</b>	<b>67,513</b>	<b>67,648</b>
2	<b>Current Assets</b>		
	(a) Financial Assets		
	(i) Cash & Cash Equivalents	12,539	6,058
	(ii) Bnk Balances other than (i) above	55,000	55,000
	(iii) Other Financial Assets	1,820	1,446
	(b) Current Tax Assets	119	-
	<b>Total Current Assets</b>	<b>69,478</b>	<b>62,504</b>
	<b>TOTAL ASSETS</b>	<b>1,36,991</b>	<b>1,30,152</b>
2	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity</b>		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	1,21,590	1,13,024
	<b>Total Equity</b>	<b>1,36,590</b>	<b>1,28,024</b>
2	<b>Liabilities</b>		
1	<b>Non-Current Liabilities</b>		
	(a) Deferred Tax Liabilities (Net)	347	347
2	<b>Current Liabilities</b>		
	(a) Financial Liabilities	-	-
	(i) Other Financial Liabilities	-	119
	(b) Provisions	54	1,662
	<b>Total Current Liabilities</b>	<b>401</b>	<b>1,781</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,36,991</b>	<b>1,30,152</b>

By Order of the Board  
For Chemo - Pharma Laboratories Limited

*Ashok Somani*

Ashok Somani  
Director  
DIN : 03063364

Date : October 28, 2024  
Place : Mumbai



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2024

(Rupees in Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			UNAUDITED HALF YEAR ENDED		AUDITED YEAR ENDED
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	2,358	964	1,372	3,322	2,355	16,436
Benefit / (Charge):	-	-	-	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	3,742	1,502	3,022	5,244	5,801	1,666
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	1,688
Impact of Adjustment of MAT Credit Entitlement	-	-	-	-	-	1,078
Net Profit / (Loss) for the Period (as per AS)	6,100	2,466	4,394	8,566	8,156	12,004

For Chemo Pharma Laboratories Limited



Ashok Somani

Director

DIN : 03063364

Date: October 28, 2024

Place: Mumbai



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE CASH FLOW STATEMENT FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER 2024

(Rupees in Thousand)

PARTICULARS	Half Year Ended 30.09.2024 Unaudited	Year Ended 31.03.2024 Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit before tax and extraordinary items	8,566.09	16,436
<b>Adjustment for</b>		
Depreciation	27.24	83
Dividend received	(8.00)	(2,480)
Interest received	(2,987.25)	(5,996)
<b>Operating profit before working capital changes</b>	<b>5,598.07</b>	<b>8,042</b>
<b>Adjustment for</b>		
Increase (Decrease) in other Current Liabilities	(1,726.86)	1,581
Decrease (increase) in Current Assets	(492.41)	(721)
Purchase of Property, Plant and Equipments	-	-
<b>Cash Generated From Operation</b>	<b>(2,219.26)</b>	<b>860</b>
Taxes Paid	-	(1,666)
<b>A. Cash Flow From Operating Activities</b>	<b>3,378.81</b>	<b>7,236</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Dividend received	8.00	2,480
Interest received	2,987.25	5,996
Purchase / (Sale) of Investment	106.54	(13,723)
(Invetsment) / Proceeds from Maturity of Fixed Deposits (net)	-	-
<b>Cash Flow From Investing Activities</b>	<b>3,101.79</b>	<b>(5,247)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from ICD Re-paid / (Given)	-	(1,489)
<b>Cash Flow From Financing Activities</b>	<b>-</b>	<b>(1,489)</b>
Net increase/(decrease) in cash and cash Equivalents	6,480.60	499
Opening balance of Cash and Cash Equivalents	6,058.17	5,559
<b>Closing Balance Of Cash and Cash Equivalents</b>	<b>12,538.77</b>	<b>6,058</b>

Date : 28th October, 2024

Place : Mumbai



For Chemo Pharma Laboratories Limited

*Ashok Somani*

Ashok Somani

Director

DIN : 03063364

# Sanjay Rane & Associates LLP

CHARTERED ACCOUNTANTS

Phone : +91 (22) 4919 8585  
Email : admin@ssrane.net  
Website : www.ssraneandco.com  
LLP IN : ABZ-0863

## LIMITED REVIEW REPORT

To,

Board of Directors of **Chemo Pharma Laboratories Limited**

We have reviewed the accompanying Statement of unaudited standalone financial results of **CHEMO PHARMA LABORATORIES LIMITED** for the quarter ended September 30, 2024 and year to date results for the three months period from July 01, 2024 to September 30, 2024 ("the Statement").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates LLP

Chartered Accountants

Firm Reg. No. 121089W/W100878

  
CA. Abhijeet Deshmukh

Partner

Membership No. 129145

Date: October 20, 2024

Place: Mumbai

UDIN: 24129145BKAKLQ6283

